Description

retatrutide buy (10mg Lyophilized Powder) – Research Grade Peptide

Product Code: RETA-10MG
Formulation: Lyophilized Sterile Powder
Purity: ≥99% (by HPLC and Mass Spectrometry)
Quantity: 10mg per vial
Storage: Lyophilized: -20°C (Stable for 24 months); Reconstituted: +4°C (Use within 14 days)

 The Next Generation of Triple-Hormone Receptor Agonism

retatrutide buy (formerly known as LY3437943) represents a paradigm shift in peptide-based metabolic research. As a first-in-class triple agonist targeting the Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon-like Peptide-1 (GLP-1), and Glucagon (GCG) receptors, retatrutide buy moves beyond traditional dual agonism (GIP/GLP-1) to unlock synergistic metabolic pathways previously inaccessible in preclinical models.

This 10mg formulation is designed for advanced biomedical research and investigative laboratory applications. Unlike single- or dual-receptor agonists, retatrutide buy unique pharmacology allows scientists to study coordinated energy expenditure, appetite regulation, and hepatic lipid metabolism simultaneously.

retatrutide buy & Structural Properties

Retatrutide is a synthetic 39-amino acid peptide engineered for enhanced stability and prolonged half-life. Key structural features include:

• Molecular Formula: C₁₉₈H₃₀₈N₄₈O₆₂

• Molecular Weight: Approximately 4,500 Daltons

• Modifications: Fatty diacid side chain conjugation enabling strong albumin binding, extending the in vivo half-life suitable for weekly dosing intervals in translational studies.

• Sequence Modifications: Specific amino acid substitutions at positions 2, 13, and 20 confer balanced potency across all three receptors, avoiding biased agonism toward any single pathway.

The 10mg vial contains a white, odorless lyophilized cake that dissolves readily in sterile bacteriostatic water or acetic acid solution (0.1% to 1%) for reconstitution.

Mechanism of Action: Triple-Agonist Synergy

Understanding Retatrutide requires appreciating its three distinct but complementary mechanisms:

1. GIP Receptor Activation (Incretin Effect)

GIP agonism potentiates glucose-dependent insulin secretion from pancreatic beta cells. Unlike older compounds, Retatrutide’s GIP activity is designed to be non-desensitizing, preserving insulinotropic capacity over extended study periods. Additionally, GIP signaling in adipose tissue promotes lipid buffering—the safe storage of dietary fats rather than ectopic deposition in the liver or muscle.

2. GLP-1 Receptor Activation (Appetite & Gastric Emptying)

GLP-1 agonism slows gastric emptying, reduces appetite via central hypothalamic pathways, and enhances glucose-stimulated insulin secretion. This component provides the classic satiety signal seen in earlier peptide classes.

3. Glucagon Receptor Activation (Energy Expenditure)

This is Retatrutide’s distinguishing feature. Controlled GCG agonism increases resting energy expenditure, promotes hepatic fatty acid oxidation, and stimulates thermogenesis in brown adipose tissue (BAT). Unlike unopposed glucagon (which can cause hyperglycemia), the GIP and GLP-1 components counterbalance hepatic glucose output, resulting in net metabolic benefit without dysglycemia.

The Synergy: In animal models, the triple agonist effect produces greater weight reduction and glycemic improvement than the sum of individual components—a true synergistic interaction.

Research Applications (For Laboratory Use Only)

The 10mg dosage is ideal for the following research models:

A. Obesity & Body Composition Studies

• Dose range in rodent models: 0.1 – 1.0 mg/kg, administered subcutaneously once every 3-5 days.

• Key endpoints: Reduction in fat mass with preservation of lean mass; decreased food intake coupled with increased ambulatory activity and oxygen consumption (indirect calorimetry).

B. Non-Alcoholic Steatohepatitis (NASH) / Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

• retatrutide buy glucagon component directly reduces hepatic de novo lipogenesis. Research protocols using the 10mg vial have demonstrated significant reductions in liver fat fraction (measured by MRI-PDFF) within 4-8 weeks in diet-induced obese models.

C. Type 2 Diabetes Mellitus (T2DM) Research

• Investigate glucose homeostasis, beta-cell preservation, and insulin sensitivity. The triple agonist action lowers fasting glucose while improving first-phase insulin response.

D. Cardiovascular Metabolism

• Preliminary studies suggest improved lipid profiles (reduced triglycerides, LDL, and ApoB) and blood pressure modulation independent of weight loss.

Reconstitution & Handling Protocol

Critical for maintaining peptide integrity:

1. Allow the vial to reach room temperature (20–25°C) for 10 minutes before opening to avoid condensation.

2. Add 1.0 mL of bacteriostatic water (0.9% benzyl alcohol) or sterile acetic acid (0.1%) directed against the glass wall—not directly onto the lyophilized cake.

3. Gently swirl (do not vortex or shake vigorously) until the solution is clear and particle-free. Typical reconstitution volume yields a concentration of 10 mg/mL.

4. Withdraw desired dose using a sterile insulin syringe. For sub-milligram dosing, dilute further with sterile saline.

Note: The 10mg vial is intended for multiple use in research settings. Use aseptic technique to avoid endotoxin contamination.

Purity & Quality Assurance

Every batch of Retatratide 10mg undergoes rigorous third-party testing:

A Certificate of Analysis (COA) accompanies each shipment.

Stability & Storage

• Lyophilized (unopened): Stable for 24 months at -20°C. Avoid repeated freeze-thaw cycles.

• Reconstituted solution: Stable for 14 days at +4°C (refrigerated). For longer storage, aliquot into sterile vials and refreeze at -20°C for up to 3 months (avoid more than 2 freeze-thaw cycles).

• In-use stability: At 25°C, reconstituted solution retains >95% purity for 8 hours.